Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 18, 2026, 6:19 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 164 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Placebo Topical Gel Clear all
Completed Phase 3 Interventional Accepts healthy volunteers

Study Comparing Test to Aczone 7.5% and Both to a Placebo Control in the Treatment of Acne Vulgaris

NCT04015375
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Dapsone gel 7.5% (Torrent Pharmaceuticals Ltd), ACZONE® (dapsone) gel, 7.5% (Allergan, INC.), Placebo for Dapsone gel 7.5% (Torrent Pharmaceuticals Ltd)
Drug · Other
Lead sponsor
Torrent Pharmaceuticals Limited
Industry
Eligibility
12 Years to 40 Years
Enrollment
1,150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
11
States / cities
Sherman Oaks, California • Brandon, Florida • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2020 · Synced Sep 18, 2026, 6:19 PM EDT
Completed Phase 4 Interventional Results available

Acute Low Back Pain. Topical Diclofenac and Oral Ibuprofen.

NCT04611529
View directory record Official record
Conditions
Low Back Pain
Interventions
Ibuprofen 400 mg, Topical diclofenac
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years to 69 Years
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Sep 18, 2026, 6:19 PM EDT
Completed Phase 2 Interventional Results available

Topical NVN1000 for the Treatment of External Genital and Perianal Warts

NCT02462187
View directory record Official record
Conditions
Genital Warts, Perianal Warts
Interventions
NVN1000 8% Gel, NVN1000 16%, Vehicle, NVN1000 24%
Drug
Lead sponsor
Novan, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
15
States / cities
Fountain Valley, California • Lomita, California • San Diego, California + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2023 · Synced Sep 18, 2026, 6:19 PM EDT
Completed Phase 1Phase 2 Interventional

LUT014 for the Treatment of Radiation Induced Dermatitis in Breast Cancer Patients

NCT04261387
View directory record Official record
Conditions
Radiation Dermatitis
Interventions
LUT014 Gel, Placebo for LUT014 Gel
Drug
Lead sponsor
Lutris Pharma Ltd.
Industry
Eligibility
18 Years and older · Female only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
2
States / cities
Columbus, Georgia • Shreveport, Louisiana
Source: ClinicalTrials.gov public record
Updated Jul 26, 2022 · Synced Sep 18, 2026, 6:19 PM EDT
Completed Phase 2 Interventional

Phase 2 Study of HL-009 Liposomal Gel to Treat Mild to Moderate Atopic Dermatitis

NCT01568489
View directory record Official record
Conditions
Mild to Moderate Atopic Dermatitis
Interventions
HL-009 Liposomal Gel, Placebo
Drug
Lead sponsor
HanAll BioPharma Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
7
States / cities
Arlington Heights, Illinois • Fridley, Minnesota • Berlin, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2025 · Synced Sep 18, 2026, 6:19 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Double-blind Placebo-controlled Trial of Generic Clindamycin/Benzoyl Peroxide Gel Versus Onexton Gel in Acne Vulgaris

NCT02616614
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Onexton, Clindamycin/benzoyl peroxide gel, Placebo
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
12 Years to 40 Years
Enrollment
862 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
17
States / cities
Phoenix, Arizona • Chula Vista, California • La Mesa, California + 14 more
Source: ClinicalTrials.gov public record
Updated May 26, 2020 · Synced Sep 18, 2026, 6:19 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Efficacy and Safety Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines

NCT00968942
View directory record Official record
Conditions
Lateral Canthal Lines, Crow's Feet, Facial Wrinkles
Interventions
Botulinum Toxin Type A, Placebo
Drug
Lead sponsor
Revance Therapeutics, Inc.
Industry
Eligibility
30 Years to 60 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Coral Gables, Florida
Source: ClinicalTrials.gov public record
Updated Nov 18, 2013 · Synced Sep 18, 2026, 6:19 PM EDT
Terminated Phase 3 Interventional

Confirmatory Study of Topical HyBryte™ vs. Placebo for the Treatment of CTCL

NCT06470451
View directory record Official record
Conditions
CTCL/ Mycosis Fungoides, CTCL, Mycosis Fungoides, Cutaneous T Cell Lymphoma
Interventions
Hypericin, Placebo
Drug
Lead sponsor
Soligenix
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
17
States / cities
Phoenix, Arizona • Scottsdale, Arizona • San Diego, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Sep 18, 2026, 6:19 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Phase I/II Study of KB103, a Topical HSV1-COL7, on DEB Patients

NCT03536143
View directory record Official record
Conditions
Dystrophic Epidermolysis Bullosa
Interventions
Topical beremagene geperpavec, Placebo gel
Biological
Lead sponsor
Krystal Biotech, Inc.
Industry
Eligibility
2 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jan 30, 2023 · Synced Sep 18, 2026, 6:19 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of NAFT-600 in Subjects With Tinea Pedis

NCT01289015
View directory record Official record
Conditions
Tinea Pedis
Interventions
NAFT-600 ( naftin 2 % gel ), Placebo
Drug
Lead sponsor
Merz North America, Inc.
Industry
Eligibility
12 Years and older
Enrollment
855 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
22
States / cities
Phoenix, Arizona • San Diego, California • San Francisco, California + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2013 · Synced Sep 18, 2026, 6:19 PM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

StrataXRT in Preventing Radiation Dermatitis in Pediatric Patients Undergoing Radiation Therapy to the Brain or Spinal Cord

NCT03990597
View directory record Official record
Conditions
Central Nervous System Sarcoma, Ependymoma, Glioma, Malignant Intracranial Germ Cell Tumor, Medulloblastoma, Pineoblastoma, Primary Central Nervous System Neoplasm
Interventions
Placebo Administration, Questionnaire Administration, Wound Dressing Material
Other · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
2 Years to 17 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 8, 2024 · Synced Sep 18, 2026, 6:19 PM EDT
Not listed Phase 2 Interventional

Topical 2% Povidone-Iodine Gel in Verruca Vulgaris

NCT04253912
View directory record Official record
Conditions
Warts
Interventions
VBP-245, Placebo Gel (no Povidone-Iodine)
Drug
Lead sponsor
Veloce BioPharma LLC
Industry
Eligibility
8 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
7
States / cities
Hunt Valley, Maryland • Plymouth Meeting, Pennsylvania • Sugarloaf, Pennsylvania + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2021 · Synced Sep 18, 2026, 6:19 PM EDT
Completed Phase 3 Interventional Results available

To Study Generic Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel (Glenmark Generics, Ltd) in the Treatment of Acne Vulgaris.

NCT02465632
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel, BenzaClin® Topical Gel, Clindamycin 1%/Benzoyl Peroxide 5%, Placebo
Drug
Lead sponsor
Glenmark Pharmaceuticals Ltd. India
Industry
Eligibility
12 Years to 40 Years
Enrollment
1,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
13
States / cities
Anaheim, California • Long Beach, California • Los Angeles, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2017 · Synced Sep 18, 2026, 6:19 PM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Effects of MRSA Bactericidal Gel To Promote Healing and Eliminate MRSA in cSSTI Vancogel(TM)

NCT00945152
View directory record Official record
Conditions
Bacterial Infections, Wounds
Interventions
Vancomycin 1.25-1.50% in a complex gel formulation trademarked Vancogel(R), Placebo, complex gel formulation without Vancomycin
Drug
Lead sponsor
Robert S Berman MD
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2024
U.S. locations
1
States / cities
Jupiter, Florida
Source: ClinicalTrials.gov public record
Updated Jul 20, 2022 · Synced Sep 18, 2026, 6:19 PM EDT
Completed Phase 3 Interventional Results available

Multi-center, Randomized, Double-blind Efficacy and Safety of CD0271 0.3%/CD1579 2.5 % Topical Gel in Acne Vulgaris

NCT01880320
View directory record Official record
Conditions
Acne Vulgaris
Interventions
CD0271 0.3% / CD1579 2.5%, CD0271 0.1% / CD1579 2.5%, Topical Gel Vehicle
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
12 Years and older
Enrollment
503 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
25
States / cities
Birmingham, Alabama • Mobile, Alabama • Hot Springs, Arkansas + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2018 · Synced Sep 18, 2026, 6:19 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Diclofenac Sodium Topical Gel 1% Applied 4 Times Daily in Subjects With Acute Ankle Sprain

NCT01255423
View directory record Official record
Conditions
Ankle Sprain
Interventions
Diclofenac sodium topical gel 1%, Placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
9
States / cities
Birmingham, Alabama • Aventura, Florida • Hialeah, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2012 · Synced Sep 18, 2026, 6:19 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Topical Ibuprofen for Delayed Onset Mulscle Soreness

NCT01794923
View directory record Official record
Conditions
Pain
Interventions
IBU BID, Placebo BID, IBU TID, Placebo TID
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
205 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 29, 2021 · Synced Sep 18, 2026, 6:19 PM EDT
Terminated Phase 4 Interventional Results available

TOM: Testosterone in Older Men With Sarcopenia

NCT00240981
View directory record Official record
Conditions
Sarcopenia, Hypogonadism, Muscular Diseases
Interventions
Topical testosterone gel 1% (active formulation), Topical gel (placebo formulation)
Drug
Lead sponsor
Boston Medical Center
Other
Eligibility
65 Years and older · Male only
Enrollment
209 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 22, 2017 · Synced Sep 18, 2026, 6:19 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of DSC127 in Treating Subjects With Diabetic Ulcers

NCT00796744
View directory record Official record
Conditions
Foot Ulcer, Diabetic, Diabetic Foot
Interventions
NorLeu3-A(1-7) in a gel formulation
Drug
Lead sponsor
US Biotest, Inc.
Industry
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
12
States / cities
Tucson, Arizona • Castro Valley, California • San Diego, California + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2012 · Synced Sep 18, 2026, 6:19 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Rectal Microbicide Safety and Acceptability Trial of Topically Applied Tenofovir Compared With Oral Tablet

NCT00984971
View directory record Official record
Conditions
HIV Prevention, HIV Infections
Interventions
Tenofovir, HEC Placebo, Open label tenofovir tablet
Drug
Lead sponsor
CONRAD
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
2
States / cities
Los Angeles, California • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 27, 2015 · Synced Sep 18, 2026, 6:19 PM EDT
Not listed Phase 1Phase 2 Interventional

Study of PTW-002 in Patients With Dominant or Recessive Dystrophic Epidermolysis Bullosa Due to Mutation(s) in Exon 73 of the COL7A1 Gene

NCT05529134
View directory record Official record
Conditions
Dystrophic Epidermolysis Bullosa
Interventions
PTW-002 10 mg/g gel, Placebo
Drug
Lead sponsor
Phoenicis Therapeutics
Industry
Eligibility
4 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
3
States / cities
Stanford, California • Worcester, Massachusetts • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 30, 2023 · Synced Sep 18, 2026, 6:19 PM EDT
Not listed Phase 2Phase 3 Interventional Accepts healthy volunteers

Treatment of Keratoconus Using Collagen Cross-Linking

NCT00841386
View directory record Official record
Conditions
Keratoconus
Interventions
Riboflavin-5-phosphate, Sham cross-linking
Drug
Lead sponsor
University at Buffalo
Other
Eligibility
16 Years to 35 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
2
States / cities
Amherst, New York • Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Feb 10, 2009 · Synced Sep 18, 2026, 6:19 PM EDT
Not listed Phase 2 Interventional

Topical KB105 for the Treatment of TGM1-deficient Autosomal Recessive Congenital Ichthyosis (ARCI)

NCT05735158
View directory record Official record
Conditions
Autosomal Recessive Ichthyosis
Interventions
KB105, Placebo
Biological · Other
Lead sponsor
Krystal Biotech, Inc.
Industry
Eligibility
6 Months and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Rancho Santa Margarita, California
Source: ClinicalTrials.gov public record
Updated Feb 22, 2023 · Synced Sep 18, 2026, 6:19 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of UC-781 Vaginal Microbicide

NCT00132444
View directory record Official record
Conditions
HIV Infections
Interventions
topical vaginal application of UC-781 gel
Drug
Lead sponsor
CONRAD
Other
Eligibility
18 Years to 45 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 6, 2010 · Synced Sep 18, 2026, 6:19 PM EDT